DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,281,515 B1 Demeo Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,281,515 B1 Demeo Et Al USOO6281515B1 (12) United States Patent (10) Patent No.: US 6,281,515 B1 Demeo et al. (45) Date of Patent: Aug. 28, 2001 (54) LIGHTWEIGHT RADIATION PROTECTIVE 5,140,710 8/1992 Rademacher. GARMENTS 5.245,195 9/1993 Shah et al. ........................ 250/515.1 5,446,925 9/1995 Baker et al. (75) Inventors: Ronald Demeo, Miami Beach; Marcus SE2- 1-2 : 3.E. SRaCWalacle al. ....................... 250/519.1 into North Miami Beach, both of 5,525,408 6/1996 Weir et al. 5,856,415 1/1999 Lagace et al.. (73) Assignee: Meridian Research and Development, * cited by examiner POmpano Beach,Beacn, FL (US)(US Primary Examiner Jack Berman (*) Notice: Subject to any disclaimer, the term of this ASSistant Examiner—Johnnie L. Smith, II patent is extended or adjusted under 35 (74) Attorney, Agent, or Firm Townsend and Townsend U.S.C. 154(b) by 0 days. and Crew LLP, Guy W. Chambers, Esq. (57) ABSTRACT (21) Appl. No.: 09/206,671 A lightweight,9. 9. breathable garment9. which has radiopaquepad (22) Filed: Dec. 7, 1998 qualities and a method for making the radiopaque garment. (51) Int. CI.7 B21F 3/02 In a preferred embodiment, a lightweight fabric, Such as a (52)52) U. s C-rry - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 250/516.1 iscloth impregnated Surgical mask with liner a lightweight (24) or an entire radiopaque Surgical compound, mask (10), (58) Field of Search .............................. 259515.1; 519.1, Such as a barium Sulfate compound, to impart radiopaque 250/516.1; 428/551 qualities. Impregnation of the lightweight radiopaque com pound can be performed in any number of ways including (56) References Cited Soaking the fabric in a Solution containing the lightweight U.S. PATENT DOCUMENTS radiopaque compound, using the fabric as a filter in a passing Solution of the lightweight radiopaque compound, 1,800,051 4/1931 Blanco. placing the fabric in a reaction chamber between reagent 3. to: ision Solutions whose interaction will form the lightweight radio 3.052700 9/1962 E.ds. paque compound and impregnating the fabric with one 3.164840 1/1965 Reynolds reagent and then eXposing it to a complementary reagent 3,569,713 3/1971 Via, Jr. whose reaction with the first reagent will form a lightweight 3,883,749 5/1975 Whittaker et al. radiopaque compound. In alternative embodiments, radio 3,974,104 8/1976 Foster et al. paque qualities can be imparted to garments by using one or 4,129,524 12/1978 Nagai et al.. more sheets of lightweight radiopaque material, Such as 4,429,094 1/1984 Massucco. aluminum, or weaving radiopaque metal or metallized 5. 3.E. SE threads into the garment. While a Surgical mask is provided 4913,978 .. Its 428/551 as one example, the principles of the invention can also be 4.938,233 7/1990 Orrison o applied to a broad range of other items including Surgical 5.00354 3/1991 Gould et al. hoods, hospital gowns, gloves, partitions, drapes etc. 5,016,292 5/1991 Rademacher. 5,038,047 8/1991 Still. 29 Claims, 2 Drawing Sheets U.S. Patent Aug. 28, 2001 Sheet 1 of 2 US 6,281.515 B1 U.S. Patent Aug. 28, 2001 Sheet 2 of 2 US 6,281.515 B1 US 6,281.515 B1 1 2 LIGHTWEIGHT RADATION PROTECTIVE noxic Acid, Iopromide, Iopronic Acid, Iopydol, Iopy done, GARMENTS Iothalamic Acid, Iotrolan, IoverSol, Ioxaglic Acid, Ioxilan, Ipodate, Meglumine Acetrizoate, Meglumine Ditrizoate TECHNICAL FIELD OF THE INVENTION Methiodal Sodium, Metrizamide, Metrizoic Acid, Phenobutiodil, Phentetiothalein Sodium, Propryliodone, The present invention relates primarily to garments which Sodium Iodomethamate, Sozoiodolic Acid, Thorium Oxide can protect the wearer against the hazards of exposure to and Trypanoate Sodium. In alternative embodiments, radio radiation. More particularly, the present invention relates to paque qualities can be imparted to garments by using a light breathable, lightweight garments containing radiopaque sheet of radiopaque liner, Such as aluminum, or weaving compounds, Such as barium Sulfate, that are particularly radiopaque metal or metallized threads into the garment. Suitable for use by medical professionals and patients who While a Surgical mask is provided as one example, the are exposed to radiation from medical X-rayS. principles of the invention can also be applied to a broad range of other garments including Surgical hoods, hospital BACKGROUND OF THE INVENTION gowns, gloves, drapes, partitions, covers, etc. In addition, It is very common in medicine today to use X-rays for 15 other items, Such as a eye Shield, can be attached to or diagnostic and therapeutic purposes. While these X-rays incorporated within the radiopaque garments of the present Serve a beneficial medical purpose, they can also have invention. harmful side effects for both the patient to whom the X-rays are directed and the medical workers who must administer BRIEF DESCRIPTION OF THE DRAWINGS X-rays on a day-to-day basis. FIG. 1 shows a doctor wearing a Surgical mask of the There have been a number of previous attempts to miti present invention. gate the harmful effects of X-rays through the design of FIG. 2 shows a cutaway, perspective view of the Surgical radiopaque protective garments. Typically, these radiopaque mask from FIG. 1. garments consist of a Stiff material, Such as rubber, impreg FIG. 3 shows a croSS-Sectional view of the Surgical mask nated by lead or Some other heavy metal which is capable of 25 blocking X-rayS. Examples of lead impregnated radiopaque from FIGS. 1 and 2. garments can be found in Holland's U.S. Pat. No. 3,052,799, DESCRIPTION OF THE SPECIFIC Whittaker's U.S. Pat. No. 3,883,749, Leguillon's U.S. Pat. EMBODIMENTS No. 3,045,121, Via's U.S. Pat. No. 3,569,713 and Stills U.S. FIG. 1 shows a Surgeon wearing a Surgical mask 10 of the Pat. No. 5,038,047. present mouth and nose as well as Straps 14 which holds the While the lead filled prior art garments provide a good surgical mask 10 onto the Surgeon's face. As shown in FIGS. measure of protection against the harmful effects of X-rayS, these prior art garments are often heavy, Stiff, expensive, 2 and 3, the facial portion 12 of the Surgical mask is bulky and lacking in breathability. AS Such, these garments primarily made up of three plies: an interior ply 20 situated 35 next to the Surgeon's face, an exterior ply 22 Situated on the are often uncomfortable, cumberSome and restrictive. Also, outside of the mask and a central liner 24. In its common, there are Sterility issues with these prior art garments disposable form, the interior 20 and exterior 22 plies of the because they are typically too bulky and expensive to Surgical mask 10 are made of paper and the central liner 24 dispose of after each use. is made of a breathable cloth material, Such as gauze. Plastic 40 or metal stays 26 are typically provided at the top, bottom SUMMARY OF THE INVENTION and middle of the Surgical mask 10 to help the Surgical mask The present invention provides a breathable, lightweight 10 retain its shape and enhance its Seal. garment which has radiopaque qualities and is easy to As described thus far, the Surgical mask 10 shown in produce. In the preferred embodiment, a lightweight fabric, FIGS. 1-3 is of conventional construction. A distinguishing Such as a cloth Surgical mask liner or an entire Surgical mask, 45 aspect of the present invention is inexpensively imparting is impregnated with a lightweight radiopaque compound, radiopaque qualities to Such a Surgical mask 10 without Such as barium Sulfate, to impart radiopaque qualities. Significantly diminishing its lightweight usability. These Impregnation of the lightweight radiopaque compound can radiopaque qualities can be imparted in a number of ways. be performed in any number of ways including Soaking the In one preferred embodiment, the Surgical mask of the fabric in a Solution containing the lightweight radiopaque 50 present invention can be given radiopaque qualities by, prior compound, using the fabric as a filter for a passing Solution to assembly, Soaking its liner 24 in a high concentration containing the lightweight radiopaque compound, placing Solution of lightweight radiopaque compound, Such as the fabric in a reaction chamber between reagents that can barium Sulfate, or the reagents used to form the lightweight react to form the lightweight radiopaque compound and radiopaque compound, Such as barium chloride and Sulfuric creating the fabric incorporating one radiopaque compound 55 acid reagents to form a barium Sulfate lightweight radio reagent and then exposing it to a complementary reagent paque compound. In the case of barium Sulfate, this Solution used to form the radiopaque compound. Besides barium might advantageously be a 1 or 2 molar aqueous Solution of Sulfate, other radiopaque Substances which can be used for barium Sulfate precipitate (although other concentrations the present invention include, but are not limited to, would also work). After the barium Sulfate precipitate has HYPAQUETM (which is a tradename of Nycomed Corpora 60 been given an opportunity to thoroughly impregnate the tion for Diatrizoate Meglumine Inj USP), Acetrizoate liner 24 (e.g., by Soaking overnight), the liner 24 can be Sodium, Bunamiodyl Sodium, Diatrizoate Sodium, removed from the barium Sulfate Solution and air dried. The Ethiodized Oil, Iobenzamic Acid, Iocarmic Acid, Iocetamic impregnated liner 24 can then be placed between interior 20 Acid, Iodipamide, Iodixanol, Iodized Oil, Iodoalphionic and exterior 24 plies and Sewn or Sealed into the Surgical Acid, O-Iodohippurate Sodium, Iodophthalein Sodium, 65 mask 10 in a manner that is well known in the art.
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • Amidotrizoic Acid/Barium Sulfate 1477 Imbalance Should Be Corrected Before Contrast Media Are Given
    Amidotrizoic Acid/Barium Sulfate 1477 imbalance should be corrected before contrast media are given. management of adhesive small bowel obstruction;2 they allow pyloric stenosis or lesions that may predispose to obstruction. Particular care is needed in patients with multiple myeloma since identification of patients who require surgery and, although they Adequate hydration should be ensured after the procedure to pre- dehydration resulting from use of contrast media may cause pre- have not been shown to relieve obstruction, they may reduce vent severe constipation. cipitation of protein in the renal tubules, leading to anuria and length of hospital stay in patients treated without surgery. It is contra-indicated in patients with gastrointestinal perforation, fatal renal failure. 1. Murshed R, et al. Meconium ileus: a ten-year review of thirty-six and should be avoided, particularly when given rectally, in those Caution is also necessary in patients with severe hypertension, patients. Eur J Pediatr Surg 1997; 7: 275–7. at risk of perforation, such as patients with acute ulcerative colitis advanced cardiac disease, phaeochromocytoma, sickle-cell dis- 2. Abbas S, et al. Oral water soluble contrast for the management or diverticulitis and after rectal or colonic biopsy, sigmoidosco- of adhesive small bowel obstruction. Available in The Cochrane ease, or hyperthyroidism or epilepsy, and in debilitated, severely Database of Systematic Reviews; Issue 3. Chichester: John Wi- py, or radiotherapy. ill, very old, or very young patients. ley; 2007 (accessed 14/07/08). Uses and Administration Amidotrizoates and other hypertonic contrast media are neuro- Preparations Barium sulfate is used as a radiographic contrast medium toxic and should not be given intrathecally; patients with sub- (p.1474) for X-ray examination of the gastrointestinal tract in- arachnoid haemorrhage may be at risk with any intravascular BP 2008: Meglumine Amidotrizoate Injection; Sodium Amidotrizoate In- jection; volving single- or double-contrast techniques or computed tom- use.
    [Show full text]
  • Intrathecal Gadolinium-Enhanced MR Cisternography in the Evaluation Of
    Intrathecal Gadolinium-Enhanced MR ORIGINAL RESEARCH Cisternography in the Evaluation of CSF Leakage H. Selcuk BACKROUND AND PURPOSE: Radiologic identification of the location of the CSF leakage is important S. Albayram for proper surgical planning and increases the chance of dural repair. This article describes our experience in analyzing clinically suspected cranial CSF fistulas by using MR imaging combined with H. Ozer the intrathecal administration of a gadolinium-based contrast agent. S. Ulus MATERIALS AND METHODS: A total of 85 consecutive patients with suspected CSF fistulas who G.Z. Sanus presented with persistent or intermittent rhinorrhea or otorrhea lasting for more than 1 month between M.Y. Kaynar 2003 and 2007 were included in this study. N. Kocer RESULTS: We observed objective CSF leakage in 64 of 85 patients (75%). The CSF leak was located C. Islak in the ethmoidal region in 37 patients (58%), in the superior wall of the sphenoid sinus in 8 patients (13%), in the posterior wall of the frontal sinus in 10 patients (15%), in the superior wall of the mastoid air cells in 6 patients (9%), and from the skull base into the infratemporal fossa in 1 patient (2%). Two patients (3%) showed leakage into Ͼ1 paranasal sinus. CONCLUSIONS: MR cisternography after the intrathecal administration of gadopentate dimeglumine represents an effective and minimally invasive method for evaluating suspected CSF fistulas along the skull base. It provides multiplanar capabilities without risk of radiation exposure and is an excellent approach to depict the anatomy of CSF spaces and CSF fistulas. SF leakage implies abnormal communication between the using this technique.19,20 In addition, the combination of CT Csubarachnoid space and the nasal or middle ear cavity.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds and Uses Thereof
    (19) TZZ¥_ ___T (11) EP 3 121 189 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 25.01.2017 Bulletin 2017/04 C07K 5/023 (2006.01) A61K 38/07 (2006.01) A61P 17/00 (2006.01) A61P 25/00 (2006.01) (21) Application number: 16162206.3 (22) Date of filing: 19.01.2012 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • MOGRABI, Josef GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 69379 Tel Aviv (IL) PL PT RO RS SE SI SK SM TR • ATLAS, Daphne 93714 Jerusalem (IL) (30) Priority: 20.01.2011 US 201161434454 P • KEYNAN, Shoshana 30.03.2011 US 201161469138 P 71702 Modiine (IL) (62) Document number(s) of the earlier application(s) in (74) Representative: Becker Kurig Straus accordance with Art. 76 EPC: Patentanwälte 12705459.1 / 2 665 742 Bavariastrasse 7 80336 München (DE) (27) Previously filed application: 19.01.2012 PCT/IL2012/000032 Remarks: This application was filed on 24-03-2016 as a (71) Applicants: divisional application to the application mentioned • Oneday - Biotech And Pharma Ltd. under INID code 62. 6789717 Tel Aviv (IL) • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Jerusalem 91390 (IL) (54) ANTIOXIDANT, ANTI-INFLAMMATORY, ANTI-RADIATION, METAL CHELATING COMPOUNDS AND USES THEREOF (57) The present invention relates to potent compounds having combined antioxidant, antiinflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having said properties, and to methods and uses of such short peptides in clinical and cosmetic applications.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]